Thymosin in Patient with Recurrent miscarriages

An Interventional pilot study to assess the efficacy of Thymosin therapy in patients with recurrent pregnancy loss with immune dysregulation - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080835

Enrollment

Registered

2025-02-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N96- Recurrent pregnancy loss

Interventions

Intervention1: Thymosin a1 injection is given for patient with recurrent pregnancy loss with immune dysregulation: From D1 of HRT, Two subcutaneous (1.6 mg x 2 ) injections every alternative day unt

Eligibility

Inclusion criteria

Inclusion criteria: History of recurrent pregnancy loss and abnormal immunoprofiling.

Exclusion criteria

Exclusion criteria: Female Participant having any endometrial disorder Known immunological diseases like Psoriasis,SLE, and RA etc. Known case of congenital/acquired thrombophilia. Uncorrected septate uterus, myoma and adenomyoma Thin endometrium less than 7mm despite measures to improve

Design outcomes

Primary

Measure	Time frame
Ongoing Pregnancy rateTimepoint: 12 Weeks of pregnancy	—

Secondary

Measure	Time frame
clinical pregnancy rateTimepoint: 6 weeks of gestation	—

Countries

India

Contacts

Public ContactAruna R

A4 Hospital and Fertility centre

aruna@a4fertility.com09841269578

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026